Hepatitis C Virus Still Leading Cause of Hepatocellular Cancer in Men
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Sept. 7, 2023 -- The leading cause of hepatocellular carcinoma (HCC) is still hepatitis C virus (HCV) among men, but the rates of HCV-HCC have decreased since 2015, according to a study published online Sept. 5 in Clinical Gastroenterology and Hepatology.
Paulo S. Pinheiro, M.D., Ph.D., from the University of Miami School of Medicine, and colleagues examined the predominant etiology of each of 14,420 HCC cases from the Florida statewide cancer registry diagnosed during 2010 to 2018. The intersection between etiology and detailed race-ethnicity was assessed using age-adjusted incidence rates (AAIR). Etiology-specific temporal trends were examined based on diagnosis year.
The researchers found that the leading cause of HCC among men remains HCV, but since 2017, the leading cause among women is nonalcoholic fatty liver disease (NAFLD). U.S.-born minority men have particularly high HCV-HCC AAIRs, including Puerto Rican, African American, and U.S.-born Mexican Americans (10.9, 8.0, and 7.6 per 100,000). Among all Hispanics and Filipinos, NAFLD was more common, while hepatitis B virus (HBV)-HCC was more common among Asian and Haitian Black men. In Asian women, HCV-HCC surpassed HBV-HCC. Since 2015, there was a rapid decline in population-based HCV-HCC rates (−9.6 percent annually), while increases were seen in alcohol-related liver disease-HCC and NAFLD-HCC (+6.0 and 4.3 percent, respectively).
"Cancer control efforts should begin by expanding screening programs to the most vulnerable groups noted in the study," coauthor Patricia D. Jones, M.D., also from the University of Miami School of Medicine, said in a statement.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Higher Hepatitis C Virus Cure Rates Seen With Facilitated Telemedicine
FRIDAY, April 12, 2024 -- Significantly higher hepatitis C virus cure rates are seen for patients receiving opioid treatment program-integrated facilitated telemedicine versus...
Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer
MONDAY, Jan. 29, 2024 -- For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial...
Guideline Updated for Managing Hepatitis C in Chronic Kidney Disease
TUESDAY, Dec. 12, 2023 -- The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on prevention, diagnosis, evaluation, and treatment of hepatitis C in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.